Pfizer disclosed that it would increase the price of 41 drugs; 37 drugs will see price increases of 5%, 1 drug by 9%, and 3 drugs by 3% on January 15, 2019. The announcement was met with pushback from politicians who have been vocal about drug pricing concerns.
In early November 2018, outgoing Pfizer CEO Ian Read announced that the company will be returning to “business as normal” in regard to its drug pricing in January 2019, after agreeing to hold off on price hikes due to pressure from the Trump administration earlier this year.
Within the announcement, Pfizer disclosed that it would increase the price of 41 drugs; 37 drugs will see price increases of 5%, 1 drug by 9%, and 3 drugs by 3% on January 15, 2019.
The announcement was met with pushback from politicians who have been vocal about drug pricing concerns. Earlier this week, Senator Tammy Baldwin, D-Wisconsin, sent a letter to Read, expressing concern over the pricing announcement and the implications it could have for patients and families.
“I am disappointed that your company has decided to continue playing political games and to raise prices once again in January instead of making a commitment to permanently reduce prescription drug prices for millions of families struggling to afford needed medications,” wrote Baldwin. Pfizer has yet to make a formal response.
This marks the second letter Baldwin has sent to Read in a matter of months. In the first letter, sent in July 2018 after Pfizer announced it would halt on raising prices, Baldwin implored the company to stop “playing games with the costs of prescription drugs that millions of Americans depend on,” and make the price reductions permanent.
In Baldwin’s most recent letter, she requests clarifications around the upcoming price hikes, such as, “What are the current list prices for each drug and what will the list prices be when price increases take effect in January?”; “Were these drugs subject to the price increase deferral that your company announced in July?”; and “For each product subject to price increases this year, please include information on: any changes in the cost of raw materials used in manufacturing; marketing and advertising expenditures; total expenditures on research and development,” among others.
“Leading drug companies’ continued inaction to address rising prices in a serious way is exactly why we need transparency and accountability,” wrote Baldwin. She cited transparency and accountability as “critical first steps” in tackling the high cost of drugs and was open to working together in order to solve the problem.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.